PLoS ONE (Jan 2015)

Chinese Herbal Medicine Treatment Improves the Overall Survival Rate of Individuals with Hypertension among Type 2 Diabetes Patients and Modulates In Vitro Smooth Muscle Cell Contractility.

  • Ying-Ju Lin,
  • Tsung-Jung Ho,
  • Yi-Chun Yeh,
  • Chi-Fung Cheng,
  • Yi-Tzone Shiao,
  • Chang-Bi Wang,
  • Wen-Kuei Chien,
  • Jin-Hua Chen,
  • Xiang Liu,
  • Hsinyi Tsang,
  • Ting-Hsu Lin,
  • Chiu-Chu Liao,
  • Shao-Mei Huang,
  • Ju-Pi Li,
  • Cheng-Wen Lin,
  • Hao-Yu Pang,
  • Jaung-Geng Lin,
  • Yu-Ching Lan,
  • Yu-Huei Liu,
  • Shih-Yin Chen,
  • Fuu-Jen Tsai,
  • Wen-Miin Liang

DOI
https://doi.org/10.1371/journal.pone.0145109
Journal volume & issue
Vol. 10, no. 12
p. e0145109

Abstract

Read online

Type 2 diabetes (T2D) is a chronic, multifactorial, and metabolic disorder accounting for 90% diabetes cases worldwide. Among them, almost half of T2D have hypertension, which is responsible for cardiovascular disease, morbidity, and mortality in these patients. The Chinese herbal medicine (CHM) prescription patterns of hypertension individuals among T2D patients have yet to be characterized. This study, therefore, aimed to determine their prescription patterns and evaluate the CHM effect. A cohort of one million randomly sampled cases from the National Health Insurance Research Database (NHIRD) was used to investigate the overall survival rate of CHM users, and prescription patterns. After matching CHM and non-CHM users for age, gender and date of diagnosis of hypertension, 980 subjects for each group were selected. The CHM users were characterized with slightly longer duration time from diabetes to hypertension, and more cases for hyperlipidaemia. The cumulative survival probabilities were higher in CHM users than in non-CHM users. Among these top 12 herbs, Liu-Wei-Di-Huang-Wan, Jia-Wei-Xiao-Yao-San, Dan-Shen, and Ge-Gen were the most common herbs and inhibited in vitro smooth muscle cell contractility. Our study also provides a CHM comprehensive list that may be useful in future investigation of the safety and efficacy for individuals with hypertension among type 2 diabetes patients.